ACUTE MYELOID LEUKEMIA

This early-stage study tested two drugs, AZD1775 and belinostat, in 20 adults with certain blood cancers (like acute myeloid leukemia) that came back or didn't respond to prior therapy. The main goal was to find the safest dose and check side effects. The study was stopped early,…

This study looked at people with blood cancers receiving a stem cell transplant from an unrelated donor. The goal was to compare two drug combinations (cyclosporine plus sirolimus with either MMF or post-transplant cyclophosphamide) to prevent graft-versus-host disease (GVHD), a …

This study tested a combination of two drugs, venetoclax and decitabine, in 235 people with certain blood cancers (like acute myeloid leukemia and high-risk myelodysplastic syndrome) that either came back or didn't respond to prior treatment, or in older adults who couldn't handl…

This study tested a new treatment called TCB008 for adults with acute myeloid leukemia (AML) that did not respond to standard therapy or came back after treatment. TCB008 uses specially grown immune cells from healthy donors to attack the cancer. The trial aimed to see if this th…

This study tested a drug called isatuximab added to standard chemotherapy for children aged 28 days to under 18 years whose leukemia (ALL or AML) had returned or stopped responding to treatment. The goal was to see if the combination could help achieve complete remission. The tri…

This early-phase study tested the safety and best dose of a drug called Minnelide in 27 adults with acute myeloid leukemia (AML) that had come back or not responded to standard treatments. The goal was to find the highest safe dose and see if it could help control the disease. Th…

This early-phase study tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine with or without venetoclax) in people with relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).…

This early-stage study tested a new drug called AUR103 Calcium in 27 adults with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and see how the drug worked in the body. The trial was terminated early, so no final results are …

This study tested whether a combination of venetoclax and azacytidine (or a standard chemo regimen) could prevent relapse in adults with acute myeloid leukemia (AML) who still had signs of the disease after initial treatment. The 20 participants were in remission but had measurab…

This early-stage study tested a new drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to see if it was safe and to find the best dose. Only 2 people took part before the study was stopped early.

This early-phase study tested a new cell therapy (LCAR-AMDR cells) in 4 people with acute myeloid leukemia that had come back or not responded to standard treatments. The therapy uses specially engineered immune cells to target two proteins on leukemia cells. The study was termin…

This study tested a new drug called CWP232291 combined with standard chemotherapy (cytarabine) in people whose acute myeloid leukemia (AML) had returned or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink or eliminate the c…

This study tested a new drug combo (magrolimab, azacitidine, and venetoclax) in 110 adults with acute myeloid leukemia (AML) that had come back or not responded to treatment. The goal was to find the best dose and see if the drugs could control the cancer. The trial was stopped e…

This study tested a special type of immune cell (MT-401) made from a donor's blood to treat acute myeloid leukemia (AML) after a stem cell transplant. The cells were designed to attack cancer cells while leaving healthy tissue alone. The trial aimed to see if this approach could …

This study tested a chemotherapy combination containing cladribine for people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had returned or not responded to prior treatment. The goal was to see if the treatment could wipe out signs of the disease …

This early-stage study tested a three-drug combination (uproleselan, azacitidine, and venetoclax) in 16 older or medically unfit adults with untreated acute myeloid leukemia (AML). The goal was to find the safest dose and check for side effects. The trial was terminated early, so…

This study tested a new drug (MBG453) combined with two other medicines (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for standard chemotherapy. The goal was to see if the combination could safely help more patients achieve comp…

This early-phase trial tested a new drug called SL-172154, given with standard chemotherapy drugs (azacitidine with or without venetoclax), in adults with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The study aimed to find a safe dose and check for…

This early-stage study tested a new drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This study tested a drug called sabatolimab in 24 adults and teens with acute myeloid leukemia who still had small amounts of cancer cells after a stem cell transplant. The goal was to see if sabatolimab, alone or with another drug, could prevent the leukemia from coming back wit…

This study aimed to see if an oral (pill) form of the drug cladribine works similarly to the standard IV (intravenous) version in people with certain blood cancers like leukemia. Only 3 adults were enrolled before the study was stopped early. The main goal was to check safety and…